A Study of Antidepressant Effect and Mechanism on Intranasal Delivery of BDNF-HA2TAT/AAV to Rats with Post-Stroke Depression
Open Access
- 1 March 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Neuropsychiatric Disease and Treatment
- Vol. ume 16, 637-649
- https://doi.org/10.2147/ndt.s227598
Abstract
Aim: Post-stroke depression (PSD) is one of the most frequent neuropsychiatric disorders associated with stroke characterized by depression. The neuroplasticity hypothesis postulates that loss of brain-derived neurotrophic factor (BDNF) plays a major role in pathophysiology of PSD, and restoration of it may represent a critical mechanism underlying antidepressant efficacy. Methods: In previous studies, we designed a new fusion gene, HA2TAT-BDNF, and cloned it into adenovirus associated virus (AAV) to construct the BDNF-HA2TAT/AAV for the delivery of BDNF to central nervous system (CNS) via nose-brain pathway. In this study, we used it to explore the antidepressant effects on PSD rats through behavioral and various histological methods, and try to find out its specific mechanism. Results: Compared with the control group, the PSD+AAV group showed decreased sucrose consumption percentage in the sucrose preference test (SPT) (P < 0.001) and prolonged immobility in the forced swimming test (FST) (P=0.000). However, the nasal administration of BDNF-HA2TAT/AAV reversed results of these two behavioral tests (P> 0.05, P > 0.05), showing an adequate antidepressant effect. Compared with the control group, the concentrations of BDNF mRNA and protein in the hippocampus (P< 0.05, P < 0.01) and prefrontal cortex (P < 0.01, P < 0.01) of PSD rats both decreased. Increased BDNF mRNA and protein expression was observed in the prefrontal cortex (P > 0.05, P < 0.05), without notable change in the hippocampus (P < 0.05, P < 0.001) of PSD+BDNF rats. Conclusion: These results suggest that BDNF reductions in the prefrontal cortex and hippocampus are associated with the development of post-stroke depression, and that increased levels of BDNF in the prefrontal cortex could be used as a therapeutic target to treat PSD. However, the exact mechanism of BDNF action remains unclear in this regard, hindering the wider application of our method. We expect that our research could facilitate the exploration of pathogenesis and the new treatment method of PSD.Keywords
This publication has 39 references indexed in Scilit:
- Brain-Derived Neurotrophic Factor–Mediated Downregulation of Brainstem K+–Cl– Cotransporter and Cell-Type–Specific GABA Impairment for Activation of Descending Pain FacilitationMolecular Pharmacology, 2013
- Low serum BDNF may indicate the development of PSD in patients with acute ischemic strokeInternational Journal of Geriatric Psychiatry, 2010
- Acute Stress and Chronic Stress Change Brain-Derived Neurotrophic Factor (BDNF) and Tyrosine Kinase-Coupled Receptor (TrkB) Expression in Both Young and Aged Rat HippocampusYonsei Medical Journal, 2010
- Delivery of Nerve Growth Factor to Brain Via Intranasal Administration and Enhancement of Brain UptakeJournal of Pharmaceutical Sciences, 2009
- Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s diseaseProgress in Neurobiology, 2001
- Delivery of125I-NGF to the Brain via the Olfactory RouteDrug Delivery, 1997
- Middle cerebral artery occlusion without craniectomy in rats. Which method works best?Stroke, 1993
- Chronic mild stress-induced anhedonia: A realistic animal model of depressionNeuroscience & Biobehavioral Reviews, 1992
- Localization of brain-derived neurotrophic factor mRNA to neurons in the brain by in situ hybridizationExperimental Neurology, 1990
- Reversible middle cerebral artery occlusion without craniectomy in rats.Stroke, 1989